Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Arnaldo Rivera Perez

Otology & Neurotology Columbia, MO Medical Doctor

NPI 1962482232 CMS profile 88573

525 N Keene St Ste 201, Columbia, MO 65201

Open in the dashboard

General payments

$1,867

17 records reported · program years 2019–2025

Research payments

$15,893

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Arnaldo Rivera Perez of Columbia, MO is reported in the CMS Open Payments database as having received $1,867 across 17 general payments and $15,893 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Otology & Neurotology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $17 1
2024 General $89 2
2023 General $353 5
2022 General $67 2
2021 General $86 2
2021 Research $15,893 1
2019 General $1,255 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Arnaldo Rivera Perez
  • Otology & Neurotology median
  • Middle half of Otology & Neurotology
  • National median

In program year 2025, general payments to Arnaldo Rivera Perez were reported at $17. Among 280 Otology & Neurotology profiles paid that year, the median was $411 and the middle half received between $148 and $1,608.

Show as a table
Year Arnaldo Rivera Perez Otology & Neurotology median Middle half National median
2019 $1,255 $349 $117–$1,358 $163
2020 $0 $118 $58–$325 $114
2021 $86 $186 $81–$600 $132
2022 $67 $290 $129–$938 $149
2023 $353 $335 $119–$978 $160
2024 $89 $399 $138–$1,384 $164
2025 $17 $411 $148–$1,608 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. MED-EL Corporation $1,229 8 payments
  2. Stryker Corporation $193 3 payments
  3. Cochlear Americas $187 3 payments
  4. Sanara MedTech Inc. $157 1 payment
  5. Agiliti Surgical, Inc. $54 1 payment
  6. Advanced Bionics, LLC $46 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $1,075 3 payments
  2. Food and Beverage $792 14 payments
Products named General payments · program years 2019–2025
  1. VIBRANT Soundbridge Middle Ear Implant and BONEBRIDGE System $1,110 4 payments
  2. Cochlear Nucleus CI632 cochlear implant with Slim Modiolar electrode $187 3 payments
  3. BAHA $187 3 payments
  4. OSIA OSI300 IMPLANT $187 3 payments
  5. CellerateRx $157 1 payment
  6. ENTELLUS - XPRESS ENT DILATION SYSTEM $144 1 payment
  7. Mi1250 SYNCHRONY 2 FLEXsoft $87 3 payments
  8. BCI 602 Kit $63 2 payments
  9. AcuPulse Duo $54 1 payment
  10. HIRES ULTRA CI HIFOCUS MS ELECTRODE $46 1 payment
  11. Other $133 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Hill Dermaceuticals, Inc. $15,893 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

83

Median for Otolaryngology: 297

Drug cost

$2,157

Median for Otolaryngology: $6,314

Branded share of claims

48.2%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ciprofloxacin-Dexamethasone Ciprofloxacin Hcl/Dexameth Brand 13 $1,552
Triamterene-Hydrochlorothiazid Triamterene/Hydrochlorothiazid Brand 27 $236
Topiramate Generic 17 $144
Amitriptyline Hcl Generic 11 $118
Prednisone Generic 15 $106

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$86,909

Medicare's payments for the services billed

Medicare patients

458

Average age 74

Services billed

1,134

265 women, 193 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 48%
Diabetes 27%
Depression 21%
Ischemic heart disease 20%
Osteoporosis 20%
Chronic kidney disease 16%
Cancer 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

18 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otology & Neurotology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record